At a glance
ClinicalIndex Comparison Record- ✓Suspected or confirmed glioblastoma diagnosis (Cohorts 1-3) or vestibular schwannoma (Cohort 4)
- ✓Planned surgical tumor removal as part of standard care
- ✓May include postchemotherapy, post-radiation, or post-diagnostic biopsy patients
- ✓Age 18 years or older
- ✕Received investigational drug within 30 days prior to first dose
- ✕Myocardial infarction, cerebrovascular accident, uncontrolled CHF, significant liver disease, or unstable angina within 6 months
- ✕History of infusion reactions to monoclonal antibody therapies
- ✕Pregnant or breastfeeding
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Phase I/II, Open-Label Study Evaluating the Efficacy and Pharmacokinetics of Panitumumab-IRDye800 as an Optical Imaging Agent to Detect Neoplasms During Neurosurgical Procedures
In Brief
A Phase 2 clinical trial evaluating Near-Infrared Fluorescence Imaging, Panitumumab, and 2 other interventions for Malignant Brain Neoplasm and Malignant Glioma. Currently recruiting, targeting 46 participants across 1 site.
Detailed Summary
The phase I/II trial studies the side effects and best dose of panitumumab-IRDye800 in diagnosing participants with malignant glioma who undergo surgery. Panitumumab-IRDye800 can attach to tumor cells and make them more visible using a special camera during surgery, which may help surgeons better distinguish tumor cells from normal brain tissue and identify small tumors that cannot be seen using current imaging methods.
Study Details
Timeline
Interventions
Undergo NIR imaging
Given IV
Given IV
Intraoperative camera capable of exciting and detecting near infrared (NIR) dyes. Imaging will be performed on subjects during surgery and/or on ex-vivo resected tissues in the surgery suite ("back table").